(Press-News.org) Contact information: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Unraveling misfolded molecules using 'reprogrammed' yeast protein
Implications for new brain disease therapies
PHILADELPHIA - At the heart of brain diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease is protein misfolding, in which distorted proteins are unable to perform their normal functions. At present, there is no known way to reverse protein misfolding.
But James Shorter, Ph.D., associate professor of Biochemistry and Biophysics, at the Perelman School of Medicine, University of Pennsylvania, has found a possible way to unravel misfolded proteins by "reprogramming" Hsp104, a common yeast protein. The work was published this week in Cell.
Hsp104 is a "chaperone" protein, one that assists in the proper formation and functioning of other protein complexes. Although Hsp104 is one of the most common proteins on the planet, it has no analogue in humans or animals.
"We don't understand why animals have lost the gene for Hsp104, but at the same time, we've been wondering: 'Is there a therapeutic opportunity in this?'" asks Shorter. "Can we add it back as a disruptive technology to antagonize the protein misfolding that characterizes some diseases?"
In previous studies, Shorter's lab established that the natural version of Hsp104 is active against neurodegenerative proteins such as alpha-synuclein. "We expressed the wild-type protein in a rat model of Parkinson's disease and observed beneficial phenotypes," explains Shorter. "But the wild-type protein just doesn't work as well as we would like."
In the present study, the team screened large libraries of Hsp104 variants to find versions that could both maintain protein structure and break up misfolded clumps. "Luckily several variants came out of our screen that could suppress the toxicity associated with misfolded and clumped FUS, TDP-43, and alpha-synuclein disease proteins in yeast, while also enhancing proper protein function," he adds.
Shorter's team collaborated with the lab of Guy Caldwell at the University of Alabama to test Hsp104 variants in the worm C. elegans and found marked rescue of alpha-synuclein toxicity, the first time that engineered enzymes have been shown to suppress neurodegeneration in a multicellular animal.
"This is very exciting, as there are no agents that are known to rescue neurodegeneration and at the same time reverse protein misfolding," notes first author Meredith Jackrel, Ph.D., a postdoctoral fellow in the Shorter lab. "Certainly nobody's ever tried to reprogram an existing protein to try to accomplish that task."
Shorter identified Hsp104's coiled-coil middle domain as a major area affecting its ability to function as a chaperone, noting that minor mutations in this domain appear to have wide-ranging potential to unlock the molecule's protein clump-busting capabilities. He suggests that the middle domain of Hsp104 functions much like an electrical capacitor, storing the protein's beneficial possibilities. A seemingly small tweak of the middle-domain structure, as well as other parts of the molecule such as the pore loops, can unleash a surprising therapeutic power.
With that power now demonstrated in the relatively primitive worm species, the team's next step will be to move to a more complex animal model in mice, where the side effects of introducing a foreign protein into an organism might be a concern.
Shorter explains that aside from Hsp104's declumping function, "the other major goal from a bioengineering viewpoint is to make the tweaked Hsp104 specific in what it targets because all the variants we have at the moment seem to work across the board. That's not what you want for a therapeutic, because there might be off-target effects."
He stresses that although his protein reengineering approach is not yet a cure or practical treatment for neurodegenerative disease, it's a major first step toward that ultimate goal and shows that clump busting -- what was previously thought impossible -- is within reach, adding, "We've defined that it is possible to achieve clot-busting activity in a simple model system. The challenge is to move it forward from there."
INFORMATION:
The research was supported by an American Heart Association Post-Doctoral Fellowship; a National Institutes of Health (NIH) training grant (T32GM071339); an NRSA predoctoral fellowship (F31NS079009); an NIH Director's New Innovator Award (DP2OD002177); other NIH grants (R21NS067354, R21HD074510, R01GM099836); a Muscular Dystrophy Association Research Award (MDA277268), and an Ellison Medical Foundation New Scholar in Aging Award.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.
Unraveling misfolded molecules using 'reprogrammed' yeast protein
Implications for new brain disease therapies
2014-01-16
ELSE PRESS RELEASES FROM THIS DATE:
The symphony of life, revealed
2014-01-16
The symphony of life, revealed
A new imaging technique captures the vibrations of proteins, tiny motions critical to human life
BUFFALO, N.Y. — Like the strings on a violin or the pipes of an organ, the proteins in the human body vibrate in different patterns, scientists ...
How metabolism and brain activity are linked
2014-01-16
How metabolism and brain activity are linked
Study sheds light on why diet may help control seizures in epilepsy patients
A new study by scientists at McGill University and the University of Zurich shows a direct link between metabolism in brain cells and ...
Study identifies drug that could improve treatment of PTSD
2014-01-16
Study identifies drug that could improve treatment of PTSD
New study identifies drug that could improve treatment of post-traumatic stress disorder
CAMBRIDGE, Mass-- Nearly 8 million Americans suffer from posttraumatic stress disorder (PTSD), a condition ...
Preventing cell death from infection: Scientists demonstrate method to find new therapies
2014-01-16
Preventing cell death from infection: Scientists demonstrate method to find new therapies
LA JOLLA, CA—January 16, 2014—Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively ...
5,900 natural gas leaks discovered under Washington, D.C.
2014-01-16
5,900 natural gas leaks discovered under Washington, D.C.
A dozen locations had concentrations high enough to trigger explosion
DURHAM, NC – More than 5,893 leaks from aging natural gas pipelines have been found under the streets of Washington, D.C. by a research team from Duke ...
Scientists discover 2 proteins that control chandelier cell architecture
2014-01-16
Scientists discover 2 proteins that control chandelier cell architecture
Chandelier cells, a group of powerful inhibitory neurons, are important in epilepsy and schizophrenia
Cold Spring Harbor, NY – Chandelier cells are neurons that use their unique shape to ...
Research sheds new light on heritability of disease
2014-01-16
Research sheds new light on heritability of disease
Study explores the role DNA plays to predispose individuals to diseases
BOSTON - A group of international researchers, led by a research fellow in the Harvard Medical School-affiliated ...
Immune cells may heal an injured heart
2014-01-16
Immune cells may heal an injured heart
The immune system plays an important role in the heart's response to injury. But until recently, confusing data made it difficult to distinguish the immune factors that encourage the heart to heal following ...
Space station MAXI-mizing our understanding of the universe
2014-01-16
Space station MAXI-mizing our understanding of the universe
Look up at the night sky ... do you see it? The stars of the cosmos bursting in magnificent explosions of death and rebirth! No? Well, then maybe you are not looking through the "eyes" of the Monitor ...
Unsafe at any level
2014-01-16
Unsafe at any level
Very low blood alcohol content associated with causing car crashes
Even "minimally buzzed" drivers are more often to blame for fatal car crashes than the sober drivers they collide with, reports a University of California, San Diego ...
LAST 30 PRESS RELEASES:
Engineers develop a better way to deliver long-lasting drugs
MIT scientists engineer starfish cells to shape-shift in response to light
Research spotlight: A generalized epilepsy network derived from brain abnormalities and deep brain stimulation
IMDEA Networks revolutionizes 6G networks with DISCO6G project: real-time communication and sensing
Do-it-yourself box filter clears the air of indoor pollutants
Twice as many men recover erectile function after improved prostate cancer surgery
Childhood tuberculosis cases up by 26% in the EU/EEA
Study shows almost all people claiming Universal Credit struggle to afford to eat properly
Fatty liver linked to increased risk of death from several diseases
Do lifetime body weight patterns affect kidney cancer risk?
AI can predict premature deaths in people with inflammatory bowel disease
Household electricity three times more expensive than upcoming ‘eco-friendly’ aviation e-fuels, study reveals
Urine test could halve post-op scans for kidney cancer
Thousands of lives could be saved by combining two cholesterol-lowering drugs
High resolution ultrasound could enable faster prostate cancer diagnosis
Guardians of the vineyard: Canines and chemistry work to combat powdery mildew
Improving GLP-1 drug delivery by ‘painting’ it on antibodies
Second TB vaccination boosts immunity in bladder cancer patients and reduces cancer recurrence
Study of UK biobank reveals link between new-onset type 2 diabetes and some but not all obesity-related cancers
Waist circumference stronger risk marker than BMI for obesity-related cancer in men, but not women
Uncomfortable bladder tests for female incontinence can be avoided, say researchers
Waterjet surgery for an enlarged prostate can offer relief, without compromising sexual enjoyment
Study uncovers link between childhood overweight and obesity and chronic obstructive pulmonary disease in adulthood
IU professor helps pioneer groundbreaking light-driven method to create key drug compounds
Origin of life: How microbes laid the foundation for complex cells
How the brain links related memories formed close in time
Case study: Bartonella, babesia, found in brain tissue of child with seizures
“Concierge” screening for kidney transplant candidates leads to better outcomes, UNM researcher finds
New study sheds light on how bacteria ‘vaccinate’ themselves with genetic material from dormant viruses
Four advances that could change tuberculosis treatment
[Press-News.org] Unraveling misfolded molecules using 'reprogrammed' yeast proteinImplications for new brain disease therapies